54390-97-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromoisothiazole is used as a synthetic intermediate for the development of 4-nitroisothiazoles, which have potential antifungal properties. These compounds can be utilized in the creation of new antifungal agents to combat fungal infections.
Used in Chemical Synthesis:
As a derivative of isothiazole, 5-Bromoisothiazole serves as a valuable building block in the synthesis of a wide range of chemical compounds. Its unique structure and functional groups make it a useful component in the development of new molecules with various applications across different industries.

InChI:InChI=1/C3H2BrNS/c4-3-1-2-5-6-3/h1-2H

Upstream product

• 288-16-4 isothiazol 

Downstream Products

• 1021937-60-9 C₂₀H₂₅N₃S 
• 1022155-24-3 1-[4-(2,2-dimethylpropyl)-1-trityl-1H-imidazol-2-yl]-2-(4-isothiazol-5-ylphenyl)propan-2-ol 
• 675109-06-5 8-isothiazol-5-yl-3-(5-methyl-3-phenylisoxazol-4-yl)-5H-[1,2,4]triazolo[3,4-a]isoindole 

Relevant academic research and scientific papers

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

Oral drug composition for vascular endothelial growth factor inhibitor

The invention belongs to the medical field, particularly relates to an oral drug composition for inhibiting salt of a compound of formula I (shown in the description) of a VEGF, pharmaceutical use of the oral drug composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.

Injection pharmaceutical composition for vascular endothelial growth factor inhibitor

The invention belongs to the field of medicine, particularly relates to an injection pharmaceutical composition for inhibiting salt of a compound of formula I (shown in the description) of a VEGF, pharmaceutical use of the injection pharmaceutical composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.

A method for inhibiting VEGF of the solid oral pharmaceutical composition (by machine translation)

The invention belongs to the field of medicine, in particular to inhibit VEGF of the formula I compound and salt solid pharmaceutical composition, the pharmaceutical use and pharmaceutical formulations, particularly with respect to the tumor, the treatment of angiogenesis. The invention also relates to the method for synthesizing the compounds. (by machine translation)

Vascular endothelial growth factor inhibitor compound

The invention relates to a vascular endothelial growth factor inhibitor compound. The invention belongs to the medical field and particularly relates to salt of a compound of formula I (shown in the description). The invention further relates to synthetic method of the compound, pharmaceutical use of the compound and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis.

VEGF (vascular endothelial growth factor)-inhibiting dry powder inhalation pharmaceutical composition

The invention relates to a VEGF (vascular endothelial growth factor)-inhibiting dry powder inhalation pharmaceutical composition for treating respiratory diseases, especially for asthma, in particular to a dry powder inhalation pharmaceutical composition containing an active ingredient compound I or physiologically acceptable salts thereof, and one or more pharmaceutically acceptable excipients for dry powder inhalations.

VEGF (vascular endothelial growth factor)-inhibiting compound

The invention relates to a VEGF (vascular endothelial growth factor)-inhibiting compound, belongs to the field of medicine, and in particular relates to a compound of formula I and salts. The invention also relates to a method for synthesizing the compound, uses in drugs and a pharmaceutical preparation, especially for the treatment of tumors and angiogenesis.

Dry powder inhalant pharmaceutical composition for vascular endothelial growth factor inhibitor

The invention relates to a dry powder inhalant pharmaceutical composition for a vascular endothelial growth factor inhibitor for treating respiratory diseases, particularly asthma and particularly relates to a dry powder inhalant pharmaceutical composition containing an active component compound I, physically acceptable salt thereof and one or several medicine ingredients serving as a powder inhalation.

Aerosol pharmaceutical composition for inhibiting VEGF

The invention belongs to the medical field, particularly relates to an aerosol pharmaceutical composition for inhibiting a compound of formula I (shown in the description) and a salt of a VEGF, pharmaceutical use of the aerosol pharmaceutical composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.

Hydrochloride of vascular endothelial growth factor

The invention belongs to the field of medicine and particularly relates to hydrochloride of a compound I (shown in the description) of a vascular endothelial growth factor. The invention further relates to a synthetic method of the compound, pharmaceutica